Photo from Ibrahim Halil Sahin/X
Jun 2, 2025, 07:04
Ibrahim Halil Sahin: The ATOMIC trial is out!
Ibrahim Halil Sahin, Assistant Professor at UPMC Hillman Cancer Center, shared on X:
“The ATOMIC trial is out!
Question becomes what do we do with this data now knowing 100% DFS with two dose of Nivolumab and single dose of ipilumab based on NICHE-2?
Do we even need to chemotherapy ?
Why to use 5FU, a detrimental agent, for highly curable cancer with IO alone?
Additive role of Atezolizumab seems modest, was that right agent ?
So many questions remain unanswered.”
You can find more posts featuring Ibrahim Halil Sahin on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 00:35
Jun 3, 2025, 16:39